TACTILE SYSTEMS TECHNOLOGY,INC. (NASDAQ:TCMD) Files An 8-K Entry into a Material Definitive Agreement

TACTILE SYSTEMS TECHNOLOGY,INC. (NASDAQ:TCMD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement

Story continues below

On September13, 2017, Tactile Systems Technology,Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with certain of its stockholders, Galen Partners V,L.P., Galen Partners International V,L.P., Galen Management, L.L.C., Radius Venture Partners III,LP, Radius Venture Partners III (Ohio),LP and Radius Venture Partners III QP,LP (collectively, the “Selling Stockholders”), and William Blair& Company, L.L.C. and Piper Jaffray& Co., acting on behalf of themselves and the underwriters named in Schedule I thereto (the “Underwriters”), to which the Selling Stockholders agreed to sell, and the Underwriters agreed to purchase for resale to the public (the “Offering”), subject to the terms and conditions expressed therein, 3,300,000 shares of the Company’s common stock, par value $0.001 per share (the “Firm Shares”), at a price to the public of $33.00 per share. In addition, to the Purchase Agreement, the Underwriters have been granted an option, exercisable within 30 days, to purchase up to an additional 495,000 shares of the Company’s common stock from the Selling Stockholders (the “Option Shares” and together with the Firm Shares, the “Shares”) at the same purchase price. The Company will not receive any proceeds from the sale of the Shares by the Selling Stockholders. The Offering is expected to close on or about September15, 2017, subject to the satisfaction of customary closing conditions. The Purchase Agreement provides that the Company and the Selling Stockholders will indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended.

The Shares are being offered and sold to a prospectus supplement dated September13, 2017 and an accompanying base prospectus dated August31, 2017, to the Company’s existing shelf registration statement on FormS-3 (File No.333-220132) that was declared effective by the Securities and Exchange Commission on August31, 2017. The Selling Stockholders have exercised their demand registration and distribution rights to the Amended and Restated Investors’ Rights Agreement, dated as of September14, 2012, among the Selling Stockholders, Worthy Venture Resources, LLC and the Company. Jordan Davis, a member of the Company’s Board of Directors, is a managing member of Radius Venture Partners III, LLC, which is the general partner of each of Radius Venture Partners III, LP and Radius Venture Partners III QP, LP and the manager of the general partner of Radius Venture Partners III (Ohio), LP.

The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is filed as Exhibit1.1 to this Current Report on Form8-K and is incorporated by reference herein. The Purchase Agreement has been filed with this Current Report on Form8-K to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The representations and warranties have been made for the purposes of allocating contractual risk between the parties to the agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

Item 7.01 Regulation FD Disclosure

A copy of the Company’s press release announcing the pricing of the Offering is filed with this report as Exhibit99.1 and incorporated herein by reference.

The information contained in this Item 7.01 and in Exhibit99.1 is being furnished to Item 7.01 of this Current Report on Form8-K and shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), otherwise subject to liability under Section18 of the Exchange Act, or deemed to be incorporated by reference into the Company’s filings under the Securities Act of 1933 or the Exchange Act.

EX-1.1 2 a17-20550_5ex1d1.htm EX-1.1 Exhibit 1.1   3,…
To view the full exhibit click here


Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.

An ad to help with our costs